Clinical trials: active, in Serbia
Seizures, Lennox Gastaut Syndrome
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects…
- Trial name
- NCT05219617
- Testing
- Carisbamate
- Where
- 71 sites in United States, Argentina and 14 more
- Volunteers
- 252 people
- Sponsor
- SK Life Science, Inc.
Leiomyoma (Uterine Fibroids)
Prospective Study of TVRFA Treatment for FIGO Type 3-5 Uterine Fibroids
This study evaluates the effectiveness and safety of transvaginal radiofrequency ablation of myomas (TVRFAM), a minimally invasive treatment for uterine fibroids performed at our clinic as part of the study.
- Trial name
- NCT07923253
- Testing
- Radiofrequency ablation alone
- Where
- Serbia
- Volunteers
- 50 people
- Sponsor
- University of Novi Sad
Chronic Kidney Disease and Hypertension
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in…
- Trial name
- BaxDuo-Pacific (NCT06742723)
- Testing
- Baxdrostat/dapagliflozin
- Where
- 771 sites in United States, Argentina and 40 more
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
Early-stage HER2+ Breast Cancer
A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization
The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC).
- Trial name
- Close2HER (NCT07527741)
- Where
- 10 sites in Serbia
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of…
- Trial name
- NCT07476326
- Testing
- Bmab1700, Opdivo
- Where
- 46 sites in Brazil, Chile and 8 more
- Volunteers
- 120 people
- Sponsor
- Biocon Biologics UK PLC
Ulcerative Colitis
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment…
- Trial name
- ELEVATE UC OLE (NCT03950232)
- Testing
- Etrasimod
- Where
- 472 sites in United States, Argentina and 37 more
- Volunteers
- 896 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in…
- Trial name
- NCT04736706
- Testing
- Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab
- Where
- 262 sites in United States, Australia and 33 more
- Volunteers
- 1,688 people
- Sponsor
- Merck Sharp & Dohme LLC
Idiopathic Pulmonary Fibrosis
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary…
- Trial name
- NCT07284459
- Testing
- PIPE-791 Dose A, PIPE-791 Dose B
- Where
- 108 sites in Argentina, Australia and 17 more
- Volunteers
- 324 people
- Sponsor
- Contineum Therapeutics
Alzheimer's Disease Psychosis
ACP-204 in Adults With Alzheimer's Disease Psychosis
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP Substudy 1 (Phase 2) will evaluate efficacy and dose…
- Trial name
- NCT06159673
- Testing
- ACP-204
- Where
- 155 sites in United States, Brazil and 10 more
- Volunteers
- 1,074 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Multiple System Atrophy
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).
- Trial name
- TOPAS-MSA (NCT06568237)
- Testing
- TEV-56286
- Where
- 61 sites in United States, France and 6 more
- Volunteers
- 349 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Secondary Progressive Multiple Sclerosis
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with…
- Trial name
- NCT07299019
- Testing
- Orelabrutinib
- Where
- 90 sites in United States, Australia and 18 more
- Volunteers
- 990 people
- Sponsor
- Zenas BioPharma (USA), LLC
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
- Trial name
- EMERALD-3 (NCT07415044)
- Testing
- LY4268989
- Where
- 258 sites in United States, Argentina and 26 more
- Volunteers
- 1,431 people
- Sponsor
- Eli Lilly and Company
Lewy Body Dementia Psychosis
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
- Trial name
- NCT07029581
- Testing
- ACP-204
- Where
- 62 sites in United States, Bulgaria and 4 more
- Volunteers
- 180 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Multifocal Motor Neuropathy
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources.
- Trial name
- iMMersioN (NCT05988073)
- Where
- 114 sites in United States, Australia and 18 more
- Volunteers
- 413 people
- Sponsor
- argenx
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
- Trial name
- ADHERE+ (NCT04280718)
- Testing
- Efgartigimod PH20 SC
- Where
- 147 sites in United States, Austria and 22 more
- Volunteers
- 229 people
- Sponsor
- argenx
Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).
- Trial name
- NCT07241390
- Testing
- Orforglipron
- Where
- 566 sites in Argentina, Australia and 36 more
- Volunteers
- 7,140 people
- Sponsor
- Eli Lilly and Company
Arrhythmia, Bradycardia
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival…
- Conditions
- Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
- Trial name
- PPR (NCT00271180)
- Testing
- Device
- Where
- 338 sites in United States, Australia and 33 more
- Volunteers
- 20,000 people
- Sponsor
- Medtronic
Lewy Body Dementia Psychosis
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
- Trial name
- NCT07095465
- Testing
- ACP-204
- Where
- 36 sites in United States, Bulgaria and 4 more
- Volunteers
- 126 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Inflammatory Bowel Diseases, Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's…
- Trial name
- GARNET (NCT06226883)
- Testing
- MORF-057
- Where
- 224 sites in United States, Australia and 26 more
- Volunteers
- 385 people
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)